The Correlation between Proliferative Immunohistochemical Markers and Papillary Thyroid Carcinoma Aggressiveness.
extrathyroidal invasion
immunohistochemical markers
metastases
papillary thyroid carcinoma
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
04 Jan 2023
04 Jan 2023
Historique:
received:
23
12
2022
accepted:
27
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Background and Objectives: Papillary thyroid carcinoma (PTC) is one of the most common malignancies of the endocrine system. In order to improve the ability to predict tumor behavior, several studies have been conducted to search for surrogate prognostic immunohistochemical tumor markers. Objective: To evaluate the correlation between the intensity of different immunohistochemical marker staining in PTC and the risk for extrathyroidal extension and metastases. Materials and Methods: The study comprised patients who underwent hemi- or total thyroidectomy. Thyroid tissues were immunohistochemically stained for different tumor proliferative markers: Minichromosome maintenance proteins 2 (MCM2), Ki-67 labeling index, E-Cadherin, Neuropilin-1 and Metallothionein. The correlation between the intensity of each marker staining and the final diagnosis (benign neoplasm and PTC) and the correlation between the intensity of each staining and tumor extrathyroidal extension and metastases were evaluated. Results: The study included 66 patients. Staining for Metallothionein, E-Cadherin and MCM2 significantly differed between benign neoplasm (n = 22) and thyroid-confined PTC (n = 21) (p = 0.002, 0.004 and 0.005, respectively), between benign neoplasm and PTC with extrathyroidal extension (n = 11) (p = 0.001, 0.006 and 0.01, respectively), and between benign neoplasm and PTC with metastases (n = 12) (p = 0.01, <0.001 and 0.037, respectively). No staining correlated with extrathyroidal extension. The intensity of E-Cadherin staining was significantly lower in PTC with metastases than thyroid confined PTC and PTC with extrathyroidal extension (p = 0.028 and 0.021, respectively). Conclusions: Immunohistochemical staining for Metallothionein, E-Cadherin and MCM2 significantly distinguished between benign thyroid tumor and PTC. E-Cadherin staining significantly and inversely correlated with the presence of metastases.
Identifiants
pubmed: 36676734
pii: medicina59010110
doi: 10.3390/medicina59010110
pmc: PMC9862399
pii:
doi:
Substances chimiques
Cadherins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Open Access Maced J Med Sci. 2017 Mar 22;5(2):155-159
pubmed: 28507620
World J Surg. 2010 Dec;34(12):3015-21
pubmed: 20703465
J Surg Oncol. 2001 Mar;76(3):176-80
pubmed: 11276021
Cancer Lett. 2013 Jul 10;335(1):232-41
pubmed: 23435375
Ann Endocrinol (Paris). 2019 Nov;80(5-6):324-328
pubmed: 31703800
Int J Clin Exp Pathol. 2013 Dec 15;7(1):322-30
pubmed: 24427353
Diagn Pathol. 2013 Sep 20;8:155
pubmed: 24053763
Mod Pathol. 2011 Apr;24 Suppl 2:S34-43
pubmed: 21455199
Thyroid Res. 2012 Dec 28;5(1):26
pubmed: 23273222
Exp Mol Pathol. 2010 Feb;88(1):138-42
pubmed: 19818763
Clin Chim Acta. 2019 Apr;491:39-45
pubmed: 30653951
Medicine (Baltimore). 2019 Jul;98(30):e16187
pubmed: 31348230
Onco Targets Ther. 2018 Aug 20;11:5025-5034
pubmed: 30174440
Diagn Cytopathol. 2017 Aug;45(8):714-730
pubmed: 28262004
Adv Anat Pathol. 2016 Jul;23(4):244-71
pubmed: 27145091
Endocr J. 2021 Aug 28;68(8):871-880
pubmed: 33980775
Front Oncol. 2015 Jun 03;5:125
pubmed: 26090340
Cancer Cell Int. 2003 Oct 14;3(1):17
pubmed: 14613514
Adv Anat Pathol. 2011 Jan;18(1):90-7
pubmed: 21169742
Histopathology. 2006 Jun;48(7):801-7
pubmed: 16722928
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Ann Diagn Pathol. 2008 Oct;12(5):340-3
pubmed: 18774496